COMPARISON OF APIXABAN, DABIGATRAN, RIVAROXABAN, AND EDOXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0

作者：

Cohen, A. T. ^{[1
]}

Batson, S. ^{[2
]}

Hamilton, M. ^{[3
]}

Masseria, C. ^{[4
]}

Mitchell, S. ^{[2
]}

Phatak, H. ^{[3
]}

机构：

[1] Kings Coll London, London WC2R 2LS, England

[2] Abacus Int, Bicester, Oxon, England

[3] BMS, Princeton, NJ USA

[4] Pfizer Inc, New York, NY USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.768

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCV15

引用

页码：A132 / A132

页数：1

共 50 条

[1] Comparison of apixaban, dabigatran and rivaroxaban in the acute treatment and prevention of venous thromboembolism: systematic review and network meta-analysis
Cohen, A.
Fowler, H.
Hamilton, M.
Phatak, H.
Mitchell, S. A.
Liu, X. C.
Claflin, A.
Reason, T.
[J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1064 - 1064
[2] Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
Simon Mantha
Jack Ansell
[J]. Journal of Thrombosis and Thrombolysis, 2015, 39 : 155 - 165
[3] Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
Mantha, Simon
Ansell, Jack
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 155 - 165
[4] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
Cohen, A. T.
Hamilton, M.
Mitchell, S. A.
Phatak, H.
Liu, X.
Bird, A.
Tushabe, D.
Batson, S.
[J]. PLOS ONE, 2015, 10 (12):
[5] Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis
Alotaibi, G.
Alsaleh, K.
Wu, C.
McMurtry, M. S.
[J]. INTERNATIONAL ANGIOLOGY, 2014, 33 (04) : 301 - 308
[6] Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
Cohen, A. T.
Hamilton, M.
Bird, A.
Mitchell, S. A.
Li, S.
Horblyuk, R.
Batson, S.
[J]. PLOS ONE, 2016, 11 (08):
[7] Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials
Kakkos, S. K.
Kirkilesis, G. I.
Tsolakis, I. A.
[J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2014, 48 (05) : 565 - 575
[8] Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis (vol 11, e0160064, 2016)
Cohen, A. T.
Hamilton, M.
Bird, A.
Mitchell, S. A.
Li, Xiaoyan
Horblyuk, R.
Batson, S.
[J]. PLOS ONE, 2016, 11 (09):
[9] Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison
Loke, Y. K.
Kwok, C. S.
[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (01) : 111 - 124
[10] Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons
Hurst, K. V.
Lee, R.
Milosevic, I.
Handa, A.
[J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2015, 50 (01) : 126 - 127

← 1 2 3 4 5 →